deuruxolitinib phosphate · Sun Pharm Inds Inc · NDA 217900
Leqselvi
Earliest generic entry, as listed
10 Oct 2044
Blocked by patent: US 12364699. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.
Listed patents · 6 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 12364699 | use U-3976 · sets the listed date | 10 Oct 2044 |
| US 12247034 | drug substance, drug product | 10 May 2044 |
| US 12285432 | use U-3976 | 11 Aug 2042 |
| US 11919907 | drug product, use U-3976 | 21 May 2041 |
| US 10561659 | use U-3976 | 4 May 2037 |
| US 12076323 | use U-3976 | 4 May 2037 |
Exclusivities · 1 unexpired
| NCE | new chemical entity (5 years) | 25 Jul 2029 |
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 217900 · 001 · RLD | tablet, oral | EQ 8MG BASE | 10 Oct 2044 |